Efficacy and Safety of Zolpidem for Musician's Dystonia.

IF 2.5 4区医学 Q2 CLINICAL NEUROLOGY

Journal of Movement Disorders Pub Date : 2024-10-01 Epub Date: 2024-07-01 DOI:10.14802/jmd.24121

Shiro Horisawa, Kilsoo Kim, Masato Murakami, Masahiko Nishitani, Takakazu Kawamata, Takaomi Taira

{"title":"Efficacy and Safety of Zolpidem for Musician's Dystonia.","authors":"Shiro Horisawa, Kilsoo Kim, Masato Murakami, Masahiko Nishitani, Takakazu Kawamata, Takaomi Taira","doi":"10.14802/jmd.24121","DOIUrl":null,"url":null,"abstract":"Objective: The efficacy and safety of zolpidem for treating musician's dystonia are not well understood. We aimed to retrospectively investigate the efficacy and safety of zolpidem for treating musician's dystonia.Methods: We retrospectively reviewed medical records between January 2021 and December 2023 to identify patients with musician's dystonia who had been prescribed zolpidem. Tubiana's Musician's Dystonia Rating Scale (range, 1-5; lower scores indicating greater severity) was used to evaluate musician's dystonia.Results: Fifteen patients were included in this study. The mean effective dose of zolpidem was 5.3 ± 2.0 mg. The mean effective duration of zolpidem was 4.3 ± 1.2 h. With zolpidem administration, Tubiana's musician's dystonia rating scale score significantly improved from 2.2 ± 1.0 to 4.3 ± 0.8 (48.9% improvement, p < 0.001). Two patients (13.3%) discontinued the drug owing to unsatisfactory results or sleepiness.Conclusion: The results of this study suggest that zolpidem may be an alternative treatment option for musician's dystonia.","PeriodicalId":16372,"journal":{"name":"Journal of Movement Disorders","volume":" ","pages":"425-429"},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540537/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14802/jmd.24121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The efficacy and safety of zolpidem for treating musician's dystonia are not well understood. We aimed to retrospectively investigate the efficacy and safety of zolpidem for treating musician's dystonia.

Methods: We retrospectively reviewed medical records between January 2021 and December 2023 to identify patients with musician's dystonia who had been prescribed zolpidem. Tubiana's Musician's Dystonia Rating Scale (range, 1-5; lower scores indicating greater severity) was used to evaluate musician's dystonia.

Results: Fifteen patients were included in this study. The mean effective dose of zolpidem was 5.3 ± 2.0 mg. The mean effective duration of zolpidem was 4.3 ± 1.2 h. With zolpidem administration, Tubiana's musician's dystonia rating scale score significantly improved from 2.2 ± 1.0 to 4.3 ± 0.8 (48.9% improvement, p < 0.001). Two patients (13.3%) discontinued the drug owing to unsatisfactory results or sleepiness.

Conclusion: The results of this study suggest that zolpidem may be an alternative treatment option for musician's dystonia.

查看原文本刊更多论文

唑吡坦治疗音乐家肌张力障碍的疗效和安全性。

背景：唑吡坦治疗音乐家肌张力障碍的疗效和安全性尚不清楚：唑吡坦治疗音乐家肌张力障碍的疗效和安全性尚不十分清楚：我们旨在回顾性研究唑吡坦治疗音乐家肌张力障碍的疗效和安全性：我们回顾性审查了 2021 年 1 月至 2023 年 12 月期间的医疗记录，以确定曾被处方唑吡坦的音乐家肌张力障碍患者。采用 Tubiana 音乐家肌张力障碍评级量表（范围为 1-5；分数越低，表示病情越严重）来评估音乐家肌张力障碍：本研究共纳入 15 名患者。唑吡坦的平均有效剂量为 5.3±2.0 毫克。服用唑吡坦后，Tubiana 音乐家肌张力障碍评级量表评分从 2.2±1.0 显著改善至 4.3±0.8 (改善 48.9%, p)：本研究表明，唑吡坦可能是治疗音乐家肌张力障碍的一种替代疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊